PetCaseFinder

Peer-reviewed veterinary case report

Maintenance treatment for dogs with relapsed lymphoma after short

By Troedson, Karin et al.·Published in Tierarztliche Praxis. Ausgabe K, Kleintiere/Heimtiere·2021·Clinic of Small Animal Medicine, Germany·View original on PubMed

PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →

Original publication title: Maintenance treatment in relapsed canine lymphoma after a short L-CHOP protocol.

Species:
dog
LymphomaStomach & digestionDogs

Plain-English summary

A group of dogs with relapsed lymphoma were treated with a short chemotherapy protocol called L-CHOP, which helped them achieve complete remission. Afterward, they received a maintenance treatment plan that involved alternating between oral and intravenous medications every few weeks. Most dogs tolerated the treatment well, with only mild side effects, and they had a median disease-free interval of about 264 days and overall survival of around 737 days. This suggests that the maintenance treatment can be effective for dogs who have had a relapse of lymphoma after initial treatment.

People also search for: dog lymphoma treatment · canine chemotherapy side effects · dog cancer survival rates

Abstract

OBJECTIVE: A number of different rescue protocols for relapsed canine multicentric large-cell lymphoma have been described. The aim of this pilot study was to evaluate the efficacy of a maintenance treatment in dogs that experienced a second complete remission after a short L-CHOP-rescue protocol. MATERIAL AND METHODS: Included in the study were dogs experiencing the first lymphoma relapse during a treatment-free period which were treated with a short L-CHOP protocol, achieved a complete remission and were afterwards treated with a continuous maintenance phase (MP) protocol. The L-CHOP protocol consisted of weekly treatments, with at least 3 additional treatments following complete remission. Thereafter the MP protocol with 2-week treatment intervals was conducted. It consisted of alternating oral home administration of different alkylating agents and one intravenously administered cytotoxic agent of a different mechanism of action. The dogs were presented either every 4 or 6 weeks for intravenous treatment and at this time a complete blood count was performed. The durations of the first remission, disease-free interval and overall survival time were evaluated. RESULTS: A total of 20 dogs were included in the study. A median of 7 weekly applications were given before the treatment was switched to the MP protocol. During MP, 14 dogs were treated intravenously every 6 weeks and 6 dogs every 4 weeks. Haematological adverse events were mainly mild. During the L-CHOP-protocol, one septic event occurred, and 2 dogs were hospitalized due to gastrointestinal adverse events. No patient required hospitalization during the MP. Fifteen dogs completed at least one cycle in the MP and a median of 8.5 chemotherapeutic treatments were administered. The median disease-free interval was 264 days and the median overall survival time was 737 days. CONCLUSION AND CLINICAL RELEVANCE: The protocol was generally well tolerated. Since 5 patients showed disease progression during the first cycle of the MP, dogs should ideally be evaluated for minimal residual disease before being switched to the MP. The case number in the presented study was low and the treatment relatively heterogeneous. Therefore, more dogs have to be treated with the proposed protocol before general recommendations can be made.

Find similar cases for your pet

PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.

Search related cases →

Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/34157760/